by MM360 Staff | May 8, 2025 | Uncategorized
Source: CureToday articles Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian cancer with KRAS mutations. Read More
by MM360 Staff | May 8, 2025 | Uncategorized
Source: CureToday articles I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, laughter and a community of hope. Read More
by MM360 Staff | May 8, 2025 | Uncategorized
Source: CureToday articles Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer. Read More
by MM360 Staff | May 8, 2025 | Uncategorized
Source: CureToday articles Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their diagnosis. Read More
by MM360 Staff | May 8, 2025 | Uncategorized
Source: CureToday articles Panelists discuss how the EMERALD trial demonstrated elacestrant’s efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific...
by MM360 Staff | May 8, 2025 | Uncategorized
Source: CureToday articles Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting. Read...
